NLSP

NLS Pharmaceutics (NLSP) Price Target Increased by 24.47% to 9.95

The average one-year price target for NLS Pharmaceutics (NASDAQ:NLSP) has been revised to 9.94 / share. This is an increase of 24.47% from the prior estimate of 7.99 dated August 31, 2023.

The price target is an average of many targets provided by analysts. The latest targets range from a low of 6.06 to a high of 14.18 / share. The average price target represents an increase of 1,286.84% from the latest reported closing price of 0.72 / share.

What is the Fund Sentiment?

There are 21 funds or institutions reporting positions in NLS Pharmaceutics. This is an increase of 2 owner(s) or 10.53% in the last quarter. Average portfolio weight of all funds dedicated to NLSP is 0.03%, a decrease of 27.96%. Total shares owned by institutions increased in the last three months by 1.29% to 7,454K shares.

What are Other Shareholders Doing?

NLSP / NLS Pharmaceutics Ltd Shares Held by Institutions

Bvf holds 5,747K shares representing 17.72% ownership of the company. No change in the last quarter.

Armistice Capital holds 500K shares representing 1.54% ownership of the company. In it's prior filing, the firm reported owning 500K shares, representing a decrease of 0.00%. The firm decreased its portfolio allocation in NLSP by 28.32% over the last quarter.

Affinity Asset Advisors holds 400K shares representing 1.23% ownership of the company. In it's prior filing, the firm reported owning 344K shares, representing an increase of 13.98%. The firm decreased its portfolio allocation in NLSP by 10.38% over the last quarter.

J. Goldman & Co holds 204K shares representing 0.63% ownership of the company. In it's prior filing, the firm reported owning 205K shares, representing a decrease of 0.20%. The firm decreased its portfolio allocation in NLSP by 35.19% over the last quarter.

Altium Capital Management holds 200K shares representing 0.62% ownership of the company. No change in the last quarter.

NLS Pharmaceutics Background Information
(This description is provided by the company.)

NLS Pharmaceutics Ltd. is a Swiss-based clinical-stage pharmaceutical company led by an experienced management team with a track record of developing and repurposing product candidates to treat rare and complex central nervous system disorders. The Company’s lead product candidate, Quilience® is a proprietary controlled release formulation of mazindol (mazindol CR), and is being developed for the treatment of narcolepsy. Mazindol is a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, which was used for many yearsto treat patients diagnosed with narcolepsy in compassionate use programs. NLS completed a phase 2 study in the U.S. evaluating mazindol CR in adult subjects with ADHD. The study met all primary and secondary endpoints and was well-tolerated. Quilience® has received Orphan Drug Designations both in the U.S. and in Europe for the treatment of narcolepsy.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

Click to Learn More

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.